Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Germany
  4. Xetra
  5. Curasan AG
  6. News
  7. Summary
    CURK   DE000A2YPGM4

CURASAN AG

(CURK)
SummaryChartsNewsRatingsCompany 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Curasan AG and Xlife Sciences AG Cooperate in the Field of Regenerative Medicine

06/16/2021 | 02:56am EST

curasan AG and Xlife Sciences AG have initiated a collaboration in the field of regenerative medicine. Under the agreement it is intended to develop, produce, certify and market new products with a focus on the musculoskeletal area and tissue regeneration. The main emphasis of the collaboration lies on the biologization of bone substitute materials and the development of an innovative manufacturing process. In this context, on the one hand, bone replacement products are to be manufactured using 3D printing processes by a project company of Xlife Sciences AG. The first series of tests have already yielded promising results. On the other hand, carrier materials are to be optimized for improved biofunctionality with substances that promote bone growth. For this purpose, new types of modalities, so-called exosomes, are introduced into the bone substitute material. Exosomes are bioactive nanoparticles that are secreted by stem cells or obtained from human platelets; these contain, among other molecules, growth factors and microRNAs.


ę S&P Capital IQ 2021
All news about CURASAN AG
06/16Curasan AG and Xlife Sciences AG Cooperate in the Field of Regenerative Medicine
CI
06/08PBC Biomed Ltd Collaborates with curasan AG on Musculoskeletal Regeneration
CI
01/19CURASAN : Dirk Dembski new CEO at curasan AG
EQ
01/19Curasan AG Appoints Dirk Dembski as New CEO
CI
2020CURASAN AG : curasan AG postpones annual financial report 2019 to 31 July 2020
EQ
2020CURASAN AG : curasan AG and Donau Invest, Vienna, agree on a restructuring concept by an i..
EQ
2020CURASAN AG : Notification of a loss amounting to half of the equity capital in accordance ..
EQ
2020CURASAN AG : Opening of insolvency proceedings on the assets of curasan AG
EQ
2020CURASAN AG : EBITDA 2019 probably better than results forecast
EQ
2020Curasan AG Provides Revenue Guidance for the Financial Year 2019
CI
More news
Chart CURASAN AG
Duration : Period :
curasan AG Technical Analysis Chart | MarketScreener
Full-screen chart
Managers and Directors
Torben Sorensen Chief Executive Officer
Detlef Wilke Chairman-Supervisory Board
Fabian Peters Technical Director
Christine B÷hm Chief Medical Officer
Isabella de Krassny Member-Supervisory Board